Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Open-label, Not Controlled Phase Ib-II Clinical Trial to Assess the Safety and Immunologic Efficacy of Virus-specific T Lymphocytes From the Best Donor in Receptors of Hematopoietic Progenitor Allogeneic Transplant

NCT04018261 is registered in ClinicalTrials.gov with Banc de Sang i Teixits as lead sponsor.

NCT NCT04018261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04018261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Open-label, Not Controlled Phase Ib-II Clinical Trial to Assess the Safety and Immunologic Efficacy of Virus-specific T Lymphocytes From the Best Donor in Receptors of Hematopoietic Progenitor Allogeneic Transplant
Lead sponsor
Banc de Sang i Teixits
Phase
Phase 1/2
Overall status
Completed
Start date
July 4, 2019
Completion date
October 18, 2021
Enrollment
26 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cmv viremia, immunosuppression-related infectious disease